Donepezil for Alzheimer’s disease

References

• American Psychiatric Association (APA). In: Diagnostic and Statistical Manual (3rd Edition). American Psychiatric Association, WA, USA (1993).
   Google Scholar
• McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease. Report of the NINCDS-ADRDA workgroup under the auspices of the Department of Health and Human Services taskforce on Alzheimer’s disease. Neurology34, 939–944 (1984).
   PubMed Web of Science ®Google Scholar
• Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer’s disease. Int. J. Geriatr. Psychiatry22(8), 806–812 (2007).
   PubMedGoogle Scholar
• Burns A, O’Brien J. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J. Psychopharmacol.20(6), 732–755 (2006).
   PubMed Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev.25(1), CD005593 (2006).
   Google Scholar
• Wolfe MS. Therapeutic strategies for Alzheimer’s disease. Nat. Rev. Drug Discov.1, 859–866 (2002).
   PubMed Web of Science ®Google Scholar
• Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol.2, 539–547 (2003).
   PubMed Web of Science ®Google Scholar
• Chalifour RJ, McLaughlin RW, Lavoie L et al. Stereoselective interactions of peptide inhibitors with the β-amyloid peptide. J. Biol. Chem.278, 34874–34881 (2003).
   PubMed Web of Science ®Google Scholar
• Huang TH, Yang DS, Plaskos NP et al. Structural studies of soluble oligomers of the Alzheimer amyloid peptide. J. Mol. Biol.297, 73–87 (2000).
   PubMed Web of Science ®Google Scholar
• Rueter LE, Anderson DJ, Briggs CA et al. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev.10, 167–182 (2004).
   PubMedGoogle Scholar
• Guo T, Hobbs DW. Development of BACE1 inhibitors in Alzheimer’s disease. Curr. Med. Chem.13(15), 1811–1129 (2006).
   PubMed Web of Science ®Google Scholar
• Lynch G. Glutamate-based therapeutic approach: ampakine. Curr. Opin. Pharmacol.6, 82–88 (2006).
   PubMed Web of Science ®Google Scholar
• Holmes C, Wilkinson D, Dean C et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology63(2), 214–219 (2004).
   PubMed Web of Science ®Google Scholar
• Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am. J. Health Syst. Pharm.54(24), 2805–2810 (1997).
   PubMed Web of Science ®Google Scholar
• Ibach B, Haen F. Acetylcholinesterase inhibition in Alzheimer’s disease. Curr. Pharm. Des.10(3), 231–251 (2004).
   PubMed Web of Science ®Google Scholar
• Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch. Neurol.30, 113–121 (1974).
   PubMed Web of Science ®Google Scholar
• Bowen DM, Smith CB, White P et al. Chemical pathology of the organic dementias. II. Quantitative estimation of cellular changes in post-mortem brains Brain100, 427–453 (1977).
   PubMedGoogle Scholar
• Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science215, 1237–1239 (1982).
   PubMed Web of Science ®Google Scholar
• Narahashi T, Moriguchi S, Zhao X et al. Mechanisms of action of cognitive enhancers on neuroreceptors. Biol. Pharm. Bull.27(11), 1701–1706 (2004).
   PubMed Web of Science ®Google Scholar
• Claassen JA, Jansen RW. Cholinergically mediated augmentation of cerebral perfusion in AD and related cognitive disorders: the cholinergic–vascular hypothesis. J. Gerontol. A Biol. Sci. Med. Sci.61(3), 267–271 (2006).
   PubMed Web of Science ®Google Scholar
• Takatori Y. Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer’s disease. Yakugaku Zasshi126(8) 607–616 (2006).
   PubMedGoogle Scholar
• Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis. Assoc. Disord.20(2 Suppl. 1), S8–S11 (2006).
   PubMed Web of Science ®Google Scholar
• Takoda-Takatori Y, Kume T, Sugunoto M et al. Acetylcholinesterase inhibitors used in the treatment of AD prevent glutamate neurotoxicity via nicotine acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharamacology51(3), 474–486 (2006).
   PubMedGoogle Scholar
• Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in AD. Alzheimer Dis. Assoc. Disord.20(2 Suppl. 1), S8–S12 (2006).
   Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am. J. Psychiatry4, 1356–1364 (1984).
   Google Scholar
• Sramek JJ, Cutler NR. RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? Alzheimer Dis. Assoc. Disord.4, 216–227 (2000).
   Google Scholar
• Hashimoto M, Kazui H, Matsumoto K et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? Am. J. Psychiatry162(4), 676–682 (2005).
   PubMed Web of Science ®Google Scholar
• Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am. J. Psychiatry159(5), 738–745 (2002).
   PubMed Web of Science ®Google Scholar
• Krishnan KR, Charles HC, Doraiswamy PM et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am. J. Psychiatry160(11), 2003–2011 (2003).
   PubMed Web of Science ®Google Scholar
• Bencherif B, Endres CJ, Musachio JL et al. PET imaging of brain acetylcholinesterase using 11CCP-126,998, a brain selective enzyme inhibitor. Synapse45(1), 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Seltzer B. Donepezil: a review. Expert Opin. Drug Metab. Toxicol.1(3), 527–536 (2005).
   PubMedGoogle Scholar
• Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br. J. Clin. Pharmacol.46(Suppl. 1), 1–6 (1998).
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Rogers SL, Friedoff LT. Pharmacokinetic and Pharmacodynamic profile of donepezil HCL following evening administration. Br. J. Clin. Pharmacol.46(Suppl. 1), 19–24 (1998).
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Perdomo CA, Friedoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study Br. J. Clin. Pharmacol.46(Suppl. 1), 19–24 (1998).
   PubMed Web of Science ®Google Scholar
• Ravic M, Warrington S, Boyce M, Dunn K, Johnston A. Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers. Br. J. Clin. Pharmacol.58(Suppl. 1), 34–40 (2004).
   PubMed Web of Science ®Google Scholar
• Nagy CF, Kumar D, Perdomo CA, Wason S, Cullen EI, Pratt RD. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br. J. Clin. Pharmacol.58(Suppl. 1), 25–33 (2004).
   PubMed Web of Science ®Google Scholar
• Nagy CF, Kumar D, Cullen EI et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br. J. Clin. Pharmacol.58(Suppl. 1), 18–24 (2004).
   PubMed Web of Science ®Google Scholar
• Reyes JF, Vargas R, Kumar D, Cullen EI, Perdomo CA, Pratt RD. Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. Br. J. Clin. Pharmacol.58(Suppl. 1), 9–17 (2004).
   PubMed Web of Science ®Google Scholar
• Griffith P, Lichtenberg P, Goldman R, Payne-Parrish J. Safety and efficacy of donepezil in African–Americans with mild-to-moderate Alzheimer’s disease. J. Natl Med. Assoc.98(10), 1590–1597 (2006).
   PubMed Web of Science ®Google Scholar
• Alagiakrishnan K, Wong W, Blanchette PL. Use of donepezil in elderly patients with Alzheimer’s disease – a Hawaii based study. Hawaii Med. J.59(2), 57–59 (2000).
   PubMedGoogle Scholar
• Mihara M, Ohnishi A, Tomono Y et al. Pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol.31(5) 223–229 (1993).
   PubMedGoogle Scholar
• Heywood WM, Mukaetova-Ladinska EB. Sex influence on cholinesterase inhibitor treatment in elderly individuals with Alzheimer’s disease. Am. J. Geriatr. Pharmacother.4(3), 273–286 (2006).
   PubMedGoogle Scholar
• Rogers SL, Friedoff LT. Donepezil study group. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The donepezil study group. Dementia7(6), 293–303 (1996).
   PubMedGoogle Scholar
• Rogers SL, Doody RS, Mohs RC et al. Donepezil improves cognitive and global functioning: a 15 week, double-blind placebo controlled trial. Arch. Int. Med.158(9) 1021–1031 (1998).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS et al. A 24 week double-blind, placebo controlled trial in patients with Alzheimer’s disease. Neurology50(1), 136–145 (1998).
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J et al. The effects of donepezil in Alzheimer’s disease- results from a multi-national trial. Dement. Geriatr. Cogn. Disord.10(3), 237–244 (1999).
   PubMed Web of Science ®Google Scholar
• Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo controlled preservation of function survival study of donepezil in AD patients. Neurology57, 481–488 (2001).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch. Intern. Med.158, 1021–1031 (1998).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology50, 136–145 (1998).
   PubMed Web of Science ®Google Scholar
• Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology57, 489–495 (2001).
   PubMed Web of Science ®Google Scholar
• Doody RS, Geldmacher DS, Gordon B et al. Open-label, multicenter, Phase III extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch. Neurol.58, 427–433 (2001).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur. Neuropsychopharmacol.10, 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Winblad B, Wimo A, Engedal K et al. 3-year study of donepezil therapy in Alzheimer’s disease: effects of early and continuous therapy. Dement. Geriatr. Cogn. Disord.21(5–6), 353–363 (2006).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on carer burden. J. Am. Geriatr. Soc.51(6), 734–744 (2003).
   Google Scholar
• Seltzer B, Zolnouni P, Nunez M et al. Efficacy of donepezil in early-stage Alzheimer’s disease: a randomized placebo controlled trial. Arch. Neurol.61(12), 1852–1856 (2004).
   PubMed Web of Science ®Google Scholar
• Fillit HM, Gutterman EM, Brooks RL. Impact of donepezil on caregiving burden for patients with Alzhiemer’s disease. Int. Psychogeriatr.12(3) 389–401 (2000).
   PubMed Web of Science ®Google Scholar
• Salloway S, Ferris S, Kluger A et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology63(4), 651–657 (2004).
   PubMed Web of Science ®Google Scholar
• Peterson RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med.352(23), 2379–2388 (2005).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA291(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Bordier P, Garrique S, Barold SS, Bressolles N, Lanusse S, Clementy J. Significance of syncope in patients with Alzheimer’s disease treated with cholinesterase inhibitors. Europace5(4), 429–431 (2003).
   PubMed Web of Science ®Google Scholar
• Newby JV, Kenny AR, McKeith IG. Case report of donepezil associated cardiac syncope. Int. J. Geriatr. Psychiatry19(11), 1110–1112 (2004).
   PubMedGoogle Scholar
• Babic T, Zurak N. Convulsions induced by donepezil. J. Neurol. Neurosurg. Psychiatr.66(3), 410 (1999).
   PubMedGoogle Scholar
• Thacker EL, Schneeweiss S. Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients. Drug Saf.29(11), 1077–1085 (2006).
   PubMedGoogle Scholar
• Lopez-Paisa S, Olmo JP, French JV et al. Comparative analysis of mortality in patients with AD treated with donepezil or galantamine. Age Ageing35(4), 365–371 (2006).
   PubMedGoogle Scholar
• Scatena R, Martorana GE, Bottoni P et al. An update on pharmacological approaches to neurodegenerative diseases. Expert Opin. Investig. Drugs16(1), 59–72 (2007).
   PubMed Web of Science ®Google Scholar
• Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: drug efficacy, drug safety and confirmation of a pathogenic hypothesis (Alzheimer’s disease). Pharmacogenomics J.7(1), 10–28 (2007).
   PubMed Web of Science ®Google Scholar